CA3241453A1 - Methods for treating patients with an autoantibody-mediated disease - Google Patents

Methods for treating patients with an autoantibody-mediated disease

Info

Publication number
CA3241453A1
CA3241453A1 CA3241453A CA3241453A CA3241453A1 CA 3241453 A1 CA3241453 A1 CA 3241453A1 CA 3241453 A CA3241453 A CA 3241453A CA 3241453 A CA3241453 A CA 3241453A CA 3241453 A1 CA3241453 A1 CA 3241453A1
Authority
CA
Canada
Prior art keywords
autoantibody
methods
mediated disease
treating patients
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241453A
Other languages
English (en)
French (fr)
Inventor
Peter Verheesen
Magdalena SIPS
Robert Pollmann
Michael Hertl
Pascal Joly
Sebastien Calbo
Maud MAHO-VAILLANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of CA3241453A1 publication Critical patent/CA3241453A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3241453A 2022-01-17 2023-01-17 Methods for treating patients with an autoantibody-mediated disease Pending CA3241453A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263266852P 2022-01-17 2022-01-17
US63/266,852 2022-01-17
PCT/EP2023/050980 WO2023135321A1 (en) 2022-01-17 2023-01-17 Methods for treating patients with an autoantibody-mediated disease

Publications (1)

Publication Number Publication Date
CA3241453A1 true CA3241453A1 (en) 2023-07-20

Family

ID=85036487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241453A Pending CA3241453A1 (en) 2022-01-17 2023-01-17 Methods for treating patients with an autoantibody-mediated disease

Country Status (12)

Country Link
US (1) US20240369467A1 (https=)
EP (1) EP4466539A1 (https=)
JP (1) JP2025504815A (https=)
KR (1) KR20240134900A (https=)
CN (1) CN118556187A (https=)
AR (1) AR128284A1 (https=)
AU (1) AU2023207461A1 (https=)
CA (1) CA3241453A1 (https=)
IL (1) IL314322A (https=)
MX (1) MX2024007806A (https=)
TW (1) TW202333791A (https=)
WO (1) WO2023135321A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
TW202421195A (zh) * 2022-11-07 2024-06-01 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025202714A1 (en) * 2024-03-26 2025-10-02 argenx BV Methods for treating primary sjogren's syndrome using fcrn antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法

Also Published As

Publication number Publication date
WO2023135321A1 (en) 2023-07-20
MX2024007806A (es) 2024-07-04
AR128284A1 (es) 2024-04-10
AU2023207461A1 (en) 2024-07-11
EP4466539A1 (en) 2024-11-27
CN118556187A (zh) 2024-08-27
JP2025504815A (ja) 2025-02-19
TW202333791A (zh) 2023-09-01
US20240369467A1 (en) 2024-11-07
IL314322A (en) 2024-09-01
KR20240134900A (ko) 2024-09-10

Similar Documents

Publication Publication Date Title
CA3241453A1 (en) Methods for treating patients with an autoantibody-mediated disease
WO2020146684A3 (en) Apparatus and methods for bone treatment
WO2006113890A3 (en) System for indication-based medical device programming
MX2011007578A (es) Metodos para diagnosticar y tratar la disfagia.
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2024238582A3 (en) Treatment of autoimmune disorders with nk cells
AU2003220781A1 (en) Device and method for treating pressure drop and running flat phenomena associated with the tyres of a vehicle
WO2017053613A8 (en) Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
WO2011028082A3 (ko) 고주파 치료 장치 및 방법
MX2024009492A (es) Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).
EP4032915A4 (en) GRAFTING POLYMER BASED ON CONJUGATE DIETS AND METHOD FOR THE PRODUCTION THEREOF
WO2020047144A3 (en) Ophthalmic formulations, process for preparing the same and method for administering the same
WO2023240199A3 (en) Fitusiran for the treatment of hemophilia a and b
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
TW200518727A (en) Method and system for biometric surgical confirmation
WO2024155651A3 (en) Nanosheet-hydrogel composites and methods of use
US10881762B2 (en) Method for manufacturing bioinductive patch
WO2006116374A3 (en) Surface treatments for promoting selective tissue attachment to medical implants
UA100994C2 (ru) Применение десмотеплазы для лечения инсульта
EP4352521A4 (en) DIAGNOSIS AND TREATMENT BASED ON RAPID RECOGNITION
WO2023150381A8 (en) Alz-801 for use in treating a covid-19 associated neurological symptom
EP4607221A4 (en) BATTERY ANOMALE DIAGNOSTIC DEVICE AND OPERATING PROCEDURES
EP3957305A4 (en) NANOPARTICLE COMPLEX FOR THE TREATMENT OF DISEASES AND METHODS OF PRODUCTION THEREOF
WO2024216197A3 (en) Compounds and methods for treating protein aggregation diseases
CN204336976U (zh) 一种周围神经延长器

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240910

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250110